ISSN: 3005-7590
Aims and scope
IJTLD OPEN is fully compliant with Plan S. Our aim is to publish high impact Open Access research for the continuing education of academics, clinicians and other health personnel working on respiratory diseases and lung health.
Articles submitted to IJTLD and IJTLD OPEN are evaluated solely on scientific merit. IJTLD OPEN has the same values and scope as the IJTLD, with an identical Editorial Board, peer review process and acceptance criteria. The scope includes TB and its risk factors and co-morbidities alongside related areas of lung health such as asthma, bronchiectasis, COVID-19, COPD, child lung health and the hazards of tobacco and air pollution.
IJTLD OPEN is open access and therefore free to read.
Also, because authors retain copyright they can freely distribute the PDF or upload it to any website. As a consequence, open access articles are highly downloaded and more highly cited.
Click the link below to see the Table of Contents for each issue and access the content.
Authors for both IJTLD and IJTLD OPEN should submit their manuscripts via the same portal and manuscripts will be evaluated solely on scientific merit. Go to Manuscript Central at http://mc.manuscriptcentral.com/ijtld
Before submission, authors should refer to the Instructions to Authors to check that they have complied with our requirements.
We invite authors with OA funding to submit their papers (including Editorials, Original Articles, Letters and Case Series) to IJTLD OPEN.
We welcome submissions on the development of vaccines, diagnostics and medicines for the prevention, management and control of TB and all other respiratory diseases.
This includes basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.
For all queries please e-mail the Editorial Office
Sponsorship
Supplements and article series are a highly-effective way of highlighting a specific topic to researchers, clinicians and decision makers in respiratory health.
Being an Open Access journal, IJTLD OPEN has no barriers to access and can reach readers in health centres, medical, university and pharmaceutical institutes, along with civil society, patients and carers.
All content will be freely available on Ingenta.com and on the open access repository PubMed Central. We will also have regular mailings to highlight the latest sponsored content.
Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD, IJTLD OPEN and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles:
Disability, comorbidities and risk determinants at end of TB treatment in Kenya, Uganda, Zambia and Zimbabwe
Ahead of World TB Day, an article in a forthcoming issue of IJTLD OPEN assesses patients successfully completing TB treatment for comorbidities, risk determinants and disability in health facilities in Kenya, Uganda, Zambia and Zimbabwe.
TB among refugees from Ukraine in European countries
Ahead of World TB Day, an article in a forthcoming issue of IJTLD OPEN assesses TB rates in refugees from Ukraine.
Analysis of mesothelioma cases and National Cancer Registry data to assess asbestos exposure in India
An article in a forthcoming issue of PHA assesses the number of cases of mesothelioma to highlight the dangers of asbestos use in India.